Modality
ASO
MOA
TROP-2 ADC
Target
MET
Pathway
Angiogenesis
Rett
Development Pipeline
Preclinical
~Jan 2013
→ ~Apr 2014
Phase 1
~Jul 2014
→ ~Oct 2015
Phase 2
~Jan 2016
→ ~Apr 2017
Phase 3
Jul 2017
→ Oct 2031
Phase 3Current
NCT07776640
2,572 pts·Rett
2020-12→2029-02·Recruiting
NCT05100075
2,226 pts·Rett
2017-07→2031-10·Active
NCT08850554
1,075 pts·Rett
2019-01→2027-01·Completed
+1 more trial
6,841 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2027-01-149mo awayPh3 Readout· Rett
2029-02-062.9y awayPh3 Readout· Rett
2031-10-235.6y awayPh3 Readout· Rett
Trial Timeline
Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P3
Active
P3
Complet…
P3
Recruit…
P3
Complet…
Catalysts
Ph3 Readout
2027-01-14 · 9mo away
Rett
Ph3 Readout
2029-02-06 · 2.9y away
Rett
Ph3 Readout
2031-10-23 · 5.6y away
Rett
RecruitingActiveCompleted|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07776640 | Phase 3 | Rett | Recruiting | 2572 | Mayo |
| NCT05100075 | Phase 3 | Rett | Active | 2226 | UPDRS |
| NCT08850554 | Phase 3 | Rett | Completed | 1075 | EDSS |
| NCT08640596 | Phase 3 | Rett | Completed | 968 | SeizFreq |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| SNY-5783 | Sanofi | Phase 1/2 | MET | |
| BAY-6520 | Bayer | Phase 2 | AHR | |
| Bemazumab | Regeneron | Phase 1 | VEGF | |
| Sotosacituzumab | Vertex Pharma | Phase 1 | MET | |
| GMA-5010 | Genmab | Phase 3 | JAK2 | |
| INC-1582 | Incyte | Phase 1/2 | APOC3 | |
| RVM-274 | Revolution Medicines | Phase 3 | MET | |
| Surarasimod | Xenon Pharma | Phase 2 | SHP2 | |
| Talazasiran | Kymera | NDA/BLA | MET | |
| Lisonesiran | Arvinas | Phase 1/2 | PARP |